Low-grade and high-grade serous Mullerian carcinoma: Review and analysis of publicly available gene expression profiles

Abstract Objective Mullerian low grade serous carcinoma (LGSC) and high grade serous carcinoma (HGSC) have distinct molecular profiles, clinical behavior and treatment response. Our objective was to study the biological profiles of these carcinomas. Methods This study examines publicly available gen...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2013-03, Vol.128 (3), p.488-492
Main Authors: May, Taymaa, Shoni, Melina, Crum, Christopher P, Xian, Wa, Vathipadiekal, Vinod, Birrer, Michael, Rosen, Barry, Tone, Alicia, Murphy, K. Joan
Format: Article
Language:English
Subjects:
Cystadenocarcinoma, Serous - genetics
Cystadenocarcinoma, Serous - pathology
Fallopian tube carcinoma
Fallopian Tube Neoplasms - genetics
Fallopian Tube Neoplasms - pathology
Female
Gene expression analysis
Hematology, Oncology and Palliative Medicine
High-grade serous carcinoma
Humans
Low-grade serous carcinoma
Mixed Tumor, Mullerian - genetics
Mixed Tumor, Mullerian - pathology
Neoplasm Grading
Obstetrics and Gynecology
Ovarian carcinoma
Ovarian Neoplasms - genetics
Ovarian Neoplasms - pathology
Taxane resistance
Transcriptome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective Mullerian low grade serous carcinoma (LGSC) and high grade serous carcinoma (HGSC) have distinct molecular profiles, clinical behavior and treatment response. Our objective was to study the biological profiles of these carcinomas. Methods This study examines publicly available gene expression profiles of LGSC and HGSC to identify differentially expressed genes and key pathways involved in carcinogenesis and chemotherapy response. Results Our analysis supports the hypothesis that serous mullerian carcinoma develop through two different pathways yielding two distinct malignancies, namely LGSC and HGSC. Furthermore, genes potentially involved in chemotherapeutic resistance of LGSC were identified. Suppressing the levels of these genes/proteins may increase clinical response to standard chemotherapy in patients with LGSC. Conclusion In summary, this review shows the molecular profile of LGSC and HGSC through multi-center analysis of gene expression profiles of these tumors. The gene signatures of these neoplasms may potentially be used to develop disease-specific, targeted therapy for LGSC and HGSC.
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2012.12.009